TSH-based protocol, tablet instability, and absorption effects on L-T 4 bioequivalence

Thyroid

Volumn 19, Issue 2, 2009, Pages 103-110

  Eisenberg, Marisa ^a   DiStefano III, Joseph J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; LIOTHYRONINE; THYROID HORMONE; THYROTROPIN; THYROXINE;

ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG POTENCY; DRUG STABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; INTESTINE ABSORPTION; LIOTHYRONINE BLOOD LEVEL; PRIORITY JOURNAL; REGULATORY MECHANISM; TABLET FORMULATION; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

COMPUTER SIMULATION; DRUG STABILITY; HUMANS; INTESTINAL ABSORPTION; TABLETS; THERAPEUTIC EQUIVALENCY; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 59649110626     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2008.0148     Document Type: Article

References (37)

1. DeGroot LJ, Hennemann G 2002 Thyroid disease manager: the thyroid and its diseases. Available at: http://www.thyroidmanager.org/thyroidbook.htm. Accessed on: September 2004.
2. Hennessey JV 2006 Levothyroxine dosage and the limitations of current bioequivalence standards. Nat Clin Pract Endocrinol Metab 2:474-475.
3. Wartofsky L 2002 Levothyroxine: therapeutic use and regulatory issues related to bioequivalence. Expert Opin Pharmacother 3:727-732.
4. Blakesley VA, Awni W, Locke C, Ludden TM, Granneman GR, Braverman LE 2004 Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable? Thyroid 14:191-200.
5. Klein I, Danzi S 2003 Evaluation of the therapeutic efficacy of different levothyroxine preparations in the treatment of human thyroid disease. Thyroid 13:1127-1132.
6. Food and Drug Administration Center for Drug Evaluation and Research 2001 Guidance for industry: levothyroxine sodium tablets - in vivo pharmacokinetic and bioavailability studies and in vitro dissolution testing. Available at: http://www.fda.gov/cder/guidance/3645fnl.htm. Accessed on: January 2006.
7. Food and Drug Administration Center for Drug Evaluation and Research 2001 Guidance for industry: levothyroxine sodium products enforcement of August 14, 2001 compliance date and submission of new applications. Available at: http://www.fda.gov/cder/guidance/4647fnl.pdf. Accessed on: January 2008.
8. American Thyroid Association, The Endocrine Society, and American Association of Clinical Endocrinologists 2004 Joint Statement on the U.S. Food and Drug Administration's Decision Regarding Bioequivalence of Levothyroxine Sodium. Thyroid 14:486.
9. Blakesley VA 2005 Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate. AAPS J 7:E42-E46.
10. Bolton S 2005 Bioequivalence studies for levothyroxine. AAPS J 7:E47-E53.
11. Gibaldi M 2005 Bioequivalence of thyroid preparations: the final word? AAPS J 7:E59-E60.
12. Green WL 2005 New questions regarding bioequivalence of levothyroxine preparations: a clinician's response. AAPS J 7:E54-E58.
13. Hennessey JV 2003 Levothyroxine a new drug? Since when? How could that be? Thyroid 13:279-282.
14. Food and Drug Administration 2003 Advisory Committee for Pharmaceutical Science, Record of Proceedings. Available at: http://www.fda.gov/ohrms/dockets/ ac/03/transcripts/3926T2.pdf. Accessed on: January 8, 2006.
15. Eisenberg M, Samuels M, DiStefano JJ, 3rd 2006 L-T4 bioequivalence and hormone replacement studies via feedback control simulations. Thyroid 16:1279-1292.
16. Food and Drug Administration 2005 Public Meeting for Levothyroxine Sodium Therapeutic Equivalence. May 23, 2005, Washington, DC. Available at: http://www.fda.gov/cder/meeting/levothyroxine2005.htm. Accessed on: January 2008.
17. Food and Drug Administration 2006 Advisory Committee for Pharmaceutical Science, Record of Proceedings. Available at: http://www.fda.gov/ohrms/dockets/ ac/cder06.html#PharmScience. Accessed on: April 26, 2007.
18. U.S. Department of Heath and Human Services, Food and Drug Administration 1997 Federal Register 62 FR 43535. Available at: http://www.fda.gov/cder/ fedreg/fr14au97-83.htm. Accessed on: January 2008.
19. Duffy EP; Food and Drug Administration 2006 Stability of levothyroxine sodium products - Presentation made to the FDA on October 4, 2006. Available at: www.fda.gov/ohrms/dockets/AC/06/slides/2006-4228S1-01-04-Eric%20Duffy%20slides. pdf. Accessed on: April 26, 2007.
20. Patel H, Stalcup A, Dansereau R, Sakr A 2003 The effect of excipients on the stability of levothyroxine sodium pentahydrate tablets. Int J Pharm 264:35-43.
21. U.S. Department of Heath and Human Services, Food and Drug Administration 2001 FDA Enforcement Report. Available at: http://www.fda.gov/bbs/topics/ ENFORCE/2001/ENF00703.html. Accessed on: January 2008.
22. U.S. Department of Heath and Human Services, Food and Drug Administration 2005 FDA Enforcement Report. Available at: http://www.fda.gov/bbs/topics/ enforce/2005/ENF00899.html. Accessed on: January 2008.
23. U.S. Department of Heath and Human Services, Food and Drug Administration 2006 FDA Enforcement Report. Available at: http://www.fda.gov/bbs/topics/ enforce/2006/ENF00969.html. Accessed on: January 2008.
24. U.S. Department of Heath and Human Services, Food and Drug Administration 2007 FDA Enforcement Report. Available at: http://www.fda.gov/bbs/topics/ enforce/2007/ENF00993.html. Accessed on: January 2008.
25. U.S. Department of Heath and Human Services, Food and Drug Administration 2007 FDA News: FDA acts to ensure thyroid drugs don't lose potency before expiration date. Available at: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01717. html. Accessed on: January 2008.
26. Eisenberg M, Samuels M, Distefano JJ 2008 Extensions, validation & clinical applications of a feedback control system simulator of the hypothalamo-pituitary-thyroid axis. Thyroid: Accepted. (In press.)
27. Wartofsky L, Dickey RA 2005 The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab 90:5483-5488.
28. Hennessey JV, Burman KD, Wartofsky L 1985 The equivalency of two L-thyroxine preparations. Ann Intern Med 102:770-773.
29. Hennessey JV, Sherman S. Personal communication by e-mail. April 9, 2007-April 26, 2007.
30. Spencer CA, LoPresti JS, Nicoloff JT, Dlott R, Schwarzbein D 1995 Multiphasic thyrotropin responses to thyroid hormone administration in man. J Clin Endocrinol Metab 80:854-859.
31. Carr D, McLeod DT, Parry G, Thornes HM 1988 Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol (Oxf ) 28:325-333.
32. Garnick RL, Burt GF, Long DA, Bastian JW, Aldred JP 1984 High-performance liquid chromatographic assay for sodium levothyroxine in tablet formulations: content uniformity applications. J Pharm Sci 73:75-77.
33. Kazemifard AG, Moore DE, Aghazadeh A 2001 Identification and quantitation of sodium-thyroxine and its degradation products by LC using electrochemical and MS detection. J Pharm Biomed Anal 25:697-711.
34. Patel YC, Burger HG 1973 Serum triiodothyronine in health and disease. Clin Endocrinol (Oxf ) 2:339-349.
35. Patel YC, Pharoah PO, Hornabrook RW, Hetzel BS 1973 Serum triiodothyronine, thyroxine and thyroid-stimulating hormone in endemic goiter: a comparison of goitrous and nongoitrous subjects in New Guinea. J Clin Endocrinol Metab 37:783-789.
36. Won CM 1992 Kinetics of degradation of levothyroxine in aqueous solution and in solid state. Pharm Res 9:131-137.
37. Wortsman J, Papadimitriou DC, Borges M, Defesche CL 1989 Thermal inactivation of L-thyroxin. Clin Chem 35:90-92.